Simplified preparation via streptavidin of antisense oligomers/carriers nanoparticles showing improved cellular delivery in culture

Bioconjugate Chemistry

Volumn 18, Issue 4, 2007, Pages 1338-1343

  Wang, Yi ^a   Nakamura, Kayoko ^b   Liu, Xinrong ^a   Kitamura, Naoto ^b   Kubo, Atsushi ^b   Hnatowich, Donald J ^a,b  

^a UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^b KEIO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CELLS; CHOLESTEROL; CYTOLOGY; FUNCTION EVALUATION; MIXING; OLIGOMERS; PEPTIDES;

ANTISENSE; CELL ACCUMULATION; CELLULAR DELIVERY; CELLULAR UPTAKE; POLYARGININE; SIMPLE++; STREPTAVIDIN; SURVIVIN; TRANSMEMBRANE DELIVERIES; TUMOR-TARGETING;

NANOPARTICLES;

AMIDE; ANTISENSE OLIGONUCLEOTIDE; CHOLESTEROL; MESSENGER RNA; MORPHOLINE DERIVATIVE; NANOPARTICLE; OLIGOMER; PEPTIDE DERIVATIVE; PHOSPHORUS DERIVATIVE; POLYARGININE; STREPTAVIDIN; SURVIVIN; TRANSACTIVATOR PROTEIN;

ARTICLE; BIOACCUMULATION; BIOTINYLATION; CELL CULTURE; CELL STRAIN MCF 7; CONJUGATION; CONTROLLED STUDY; COVALENT BOND; GENE TARGETING; HUMAN; HUMAN CELL; ISOTOPE LABELING; MEMBRANE TRANSPORT; PROTEIN EXPRESSION; PROTEIN TARGETING;

EID: 34547161843     PISSN: 10431802     EISSN: None     Source Type: Journal    
DOI: 10.1021/bc070032c     Document Type: Article

References (26)

1. Hnatowich, D. J., and Nakamura, K. (2006) The influence of chemical stmcture of DNA and other oligomer radiopharmaceuticals on tumor delivery. Curr. Opin. Mol. Ther. 8, 136-143.
2. Tung, C. H., and Stein, S. (2000) Preparation and applications of peptide-oligonucleotide conjugates. Bioconjugate Chem. 112, 605-618.
3. Lee, H. J., and Partridge, W. H. (2001) Pharmacokinetics and delivery of tat and tat-protein conjugates to tissues in vivo. Bioconjugate Chem. 12, 995-999.
4. Lee, H. J., Boado, R. J., Braasch, D. A., Corey, D. R., and Partridge, W. M. (2002) Imaging gene expression in the brain in vivo in a transgenic mouse model of Huntington's disease with an antisense radiopharmaceutical and drug-targeting technology. J. Nucl. Med. 43, 948-956.
5. Nakamura, K., Wang, Y., Liu, X., Kubo, A. and Hnatowich, D. J. (2006) Addition of TAT, polyarginine and cholesterol carriers to MDR1 antisense DNA using streptavidin as linker. J. Nucl. Med. 47 (Suppl.), 512 p.
6. Chu, T. C., Twu, K. Y., Ellington, A. D., and Levy, M. (2006) Aptamer mediated siRNA delivery. Nucleic Acids Res. 34, e73.
7. Vives, E., Richard, J. P., Rispal, C., and LeBleu, B. (2003) TAT peptide internalization: seeking the mechanism of entry. Curr. Protein Pept. Sci. 4, 125-132.
8. Bhorade, R., Weissleder, R., Nakakoshi, T., Moore, A., and Tung, C. H. (2000) Macrocyclic chelaters with paramagnetic cations are internalized into mammalian cells via a HIV-tat derived membrane translocation peptide. Bioconjugate Chem. 11, 301-305.
9. Astriab-Fisher, A., Sergueev, D. S., Fisher, M., Shaw, B. R., and Juliano, R. L. (2000) Antisense inhibition of P-glycoprotein expression using peptide-oligonucleotide conjugates. Biochem. Pharmacol. 60, 83-90.
10. Moulton, H. M., Hase, M. C., Smith, K. M., and Iversen, P. L. (2003) HIV tat peptide enhances cellular delivery of antisense morpholino oligomers. Antisense Nucleic Acid Drug Dev. 13, 31-43.
11. Chen, C. P., Zhang, L. R., Peng, Y. F., Wang, X. B., Wang, S. Q., and Zhang, L. H. (2003) A concise method for the preparation of peptide and arginine-rich peptide-conjugated antisense oligonucleotide. Bioconjugate Chem. 14, 532-538.
12. Jiang, T., Olson, E. S., Nguyen, Q. T., Roy, M., Jennings, P. A., and Tsien, R. Y. (2004) Tumor imaging by means of proteolytic activation of cell-penetrating peptides. Proc. Natl. Acad. Sci. U.S.A. 101, 17867-17872.
13. Shiraishi, T., and Nielsen, P. E. (2006) Photochemically enhanced cellular delivery of cell penetrating peptide-PNA conjugates. FEBS Lett. 580, 1451-1456.
14. Noguchi, H., and Matsumoto, S. (2006) Protein transduction technology: a novel therapeutic perspective. Acta Med. Okayama 60, 1-11.
15. Manoharan, M. (2002) Oligonucleotide conjugates as potential antisense drugs with improved uptake, biodistribution, targeted deliver, and mechanism of action. Antisense Nucleic Acid Drug Dev. 12, 103-128.
16. Iversen P. I., Arora V., Acker A. J., Mason D. H., and Devi G. R. (2003) Efficacy of antisense morpholiono oligomer targeted to c-myc in prostate cancer xenograft murine model and a phase I safety study in humans. Clin. Cancer Res. 9, 2510-2519.
17. Winnard, P. Jr., Chang, F., Rusckowski, M., Mardirossian, G., and Hnatowich, D. J. (1997) Preparation and use of NHS-MAG3 for technetium-99m labeling of DNA. Nucl. Med. Biol. 24, 425-432.
18. Li, F., Ling, X., Huang, H., Brattain, L., Apontes, P., Wu, J., Binderup, L., and Brattain, M. G. (2005) Differential regulation of survivin expression and apoptosis by vitamin D3 compounds in two isogenic MCF-7 breast cancer cell sublines. Oncogene 24, 1385-1395.
19. 99mTc-labeled oligonucleotides in culture is influenced by their guanine content. Nucl. Med. Biol. 34, 47-54.
20. 99mTc radiolabeling of biomolecules. Nat. Protocols 1, 1477-1480.
21. 99mTc labeled morpholinos as alternatives to labeled DNAs when incubated naked. J. Nucl. Med. 43 (Suppl.), 138 p.
22. Behlke, M. A. (2005) Progress towards in vivo use of siRNAs. Mol. Ther. 12, 644-670.
23. 99mTc- antisense oligonucleotides in target tumor cells. Cancer Biother. Radiopharm. 6, 411-419.
24. 99mTc-antisense DNAs without entrapment. Mol. Imaging Biol. 5, 240-247.
25. Nakamura, K., Wang, Y., Liu, X., Kubo, A., and Hnatowich, D. J. (2006) Influence of two transfectors on delivery of 99mTc antisense DNA in tumor-bearing mice. Mol. Imaging Biol. 8, 188-192.
26. Mock, D. M., and DuBois, D. B. (1986) A sequential, solid-phase assay for biotin in physiologic fluids that correlates with expected biotin status. Anal. Biochem. 153, 272-278.